US 10,376,464 B2
Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine
Harry G. Brittain, Milford, NJ (US); and Philip V. Felice, Smithtown, NY (US)
Assigned to THEAPRIN PHARMACEUTICALS INC., Hauppauge, NY (US)
Filed by THEAPRIN PHARMACEUTICALS INC., Hauppauge, NY (US)
Filed on Oct. 3, 2016, as Appl. No. 15/284,074.
Claims priority of provisional application 62/260,043, filed on Nov. 25, 2015.
Prior Publication US 2017/0143838 A1, May 25, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 409/44 (2006.01); A61K 9/00 (2006.01); C07D 401/12 (2006.01); A61K 31/138 (2006.01); A61K 31/198 (2006.01); A61K 31/4439 (2006.01); A61K 9/14 (2006.01); C07C 217/32 (2006.01); C07C 229/24 (2006.01); C07C 237/06 (2006.01)
CPC A61K 9/0056 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/145 (2013.01); A61K 31/138 (2013.01); A61K 31/198 (2013.01); A61K 31/4439 (2013.01); C07C 217/32 (2013.01); C07C 229/24 (2013.01); C07C 237/06 (2013.01); C07D 401/12 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A water-soluble composition consisting essentially of: a cocrystal composition containing a quantity of a theanine enantiomer and a quantity of a drug from a class selected from the group consisting of adrenergic beta blockers and direct thrombin inhibitors.